AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price ...
One key reason AbbVie has outperformed the market this year is that it has performed well financially. Through the first nine ...
AbbVie’s immunology heirs Skyrizi and Rinvoq are proving booming growth to make up for once-king Humira’s continuous sales slide. With an upcoming FDA decision for Skyrizi and a new edge over a major ...
Funds like the Vanguard S&P 500 ETF have a dividend yield of 1.1%, so to find no-brainer dividend stocks to buy now, we'll want choices that far outstrip that yield, provide stability, and have a ...
After acing a study for the induction treatment of ulcerative colitis, AbbVie’s Skyrizi has snatched another win in a maintenance trial. An approval now looks within reach for 2024. Compared with ...
Skyrizi was the top Rx and over-the-counter (OTC) pharma brand during July, according to data released by iSpot.tv on Monday afternoon. Skyrizi recorded an impressions share of voice (SOV) of 5.18%, ...
People with Crohn’s disease often take medicines to help manage their condition and improve their symptoms. Some of these medicines are taken by mouth and stay inside of the digestive tract. But ...
- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe "We know many people living with psoriasis are looking for ...
Although many people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...
AbbVie has received European Commission approval of its anti-inflammation drug Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis, the pharmaceutical ...
AbbVie’s ABBV key top-line drivers are its newer immunology medicines, Rinvoq and Skyrizi. Sales of both these drugs have effectively replaced the company’s flagship drug, Humira, which began facing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback